Please find attached herewith the Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026.

29th July, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Disclosure under Regulation 34(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 34(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Business Responsibility and Sustainability Report for financial year ended 31st March, 2026. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. Thanking you Sincerely, For Alkem Laboratories Limited Divya Mewani Vice President – Legal and Deputy Company Secretary Encl: a/a Alkem Laboratories Limited The Next Shape of Growth INDEPENDENT AUDITOR’S CERTIFICATE ON CORPORATE GOVERNANCE Business Responsibility & Sustainability Report (BRSR) FY 2025-26 TO THE MEMBERS OF compliance with Corporate Governance requirements ALKEM LABORATORIES LIMITED by the Company. SECTION A: General Disclosure 1. This certificate is issued in accordance with the terms 6. We have carried out an examination of the relevant I. Details of the Listed Entity of our engagement letter dated 26 September, 2025. records of the Company in accordance with the 1 Corporate Identity Number (CIN) of the Listed Entity L00305MH1973PLC174201 Guidance Note on Certification of Corporate Governance 2 Name of the Listed Entity Alkem Laboratories Limited 2. We, Deloitte Haskins & Sells LLP, Chartered Accountants, issued by the Institute of the Chartered Accountants 3 Year of incorporation 1973 the Statutory Auditors of Alkem Laboratories Limited of India (the ICAI), the Standards on Auditing specified (“the Company”), have examined the compliance of under Section 143(10) of the Companies Act 2013, in so 4 Registered Office Address Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400013, Maharashtra, India conditions of Corporate Governance by the Company, far as applicable for the purpose of this certificate and 5 Corporate Address Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400013, for the year ended on 31 March, 2026, as stipulated as per the Guidance Note on Reports or Certificates for Maharashtra, India in regulations 17 to 27, clauses (b) to (i) of regulation Special Purposes issued by the ICAI which requires that 6 E-mail investors@alkem.com 46(2) and para C and D of Schedule V of the SEBI (Listing we comply with the ethical requirements of the Code of 7 Telephone +91-22-3982 9999 Obligations and Disclosure Requirements) Regulations, Ethics issued by the ICAI. 8 Website www.alkemlabs.com 2015 as amended (the “Listing Regulations”). 9 Financial Year for which reporting is being done 1 April, 2025 to 31 March, 2026 7. We have complied with the relevant applicable 10 Name of the Stock Exchange(s) where shares are Bombay Stock Exchange Limited (BSE); National Stock Exchange of Managements’ Responsibility requirements of the Standard on Quality Control (SQC) listed India Limited (NSE) 1, Quality Control for Firms that Perform Audits and C 3. The compliance of conditions of Corporate Governance 11 Paid-up Capital 23,91,30,000 Reviews of Historical Financial Information, and Other is the responsibility of the Management. This 12 Contact person Assurance and Related Services Engagements. responsibility includes the design, implementation Name of the Person Mr. Manish Narang (President – Legal, Company Secretary & Compliance Officer) and maintenance of internal control and procedures Opinion Telephone +91 22 3982 9999 to ensure the compliance with the conditions of the Email address investors@alkem.com Corporate Governance stipulated in Listing Regulations. 8. Based on our examination of the relevant records 13 Reporting Boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a and according to the information and explanations consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated Financial statements, taken Auditor’s Responsibility provided to us and the representations provided by together): the Management, we certify that the Company has Type of Reporting# Disclosures under this report are done on standalone - basis for Alkem 4. Our responsibility is limited to examining the procedures Laboratories Limited complied with the conditions of Corporate Governance and implementation thereof, adopted by the Company 14 Name of Assessment or Assurance provider Deloitte Haskins & Sells LLP as stipulated in regulations 17 to 27, clauses (b) to (i) for ensuring compliance with the conditions of the 15 Type of Assessment or Assurance obtained Reasonable for Core indicators of regulation 46(2) and para C and D of Schedule V Corporate Governance. It is neither an audit nor an of the Listing Regulations during the year ended expression of opinion on the financial statements of II. Product/Services 31 March, 2026. the Company. 16 Details of business activities 9. We state that such compliance is neither an assurance 5. We have examined the books of account for the year Sr. Description of Main Activity Description of Business Activity % Turnover of the Entity as to the future viability of the Company nor the ended 31 March, 2026 and other relevant records 1. Manufacturing of pharmaceutical The Company is engaged in pharmaceutical business 82.4% efficiency or effectiveness with which the Management products with global operations. The Company is engaged in the and documents maintained by the Company for the has conducted the affairs of the Company. development, manufacture and sale of pharmaceutical purposes of providing reasonable assurance on the products. 2 Trade Wholesale Trading 17.6% For Deloitte Haskins & Sells LLP 17 Products/Services sold by the entity Chartered Accountants (Firm’s Registration No. 117366W/W-100018) % of Total Turnover Sr. Product/Service NIC Code contributed 1. Pharmaceutical and nutraceutical products 210 100% Rupen K. Bhatt III. Operations (Partner) Place: Mumbai (Membership No. 046930) 18 Number of locations where plants and/or operations/offices of the entity are situated*: Date: 28 May, 2026 (UDIN: 26046930HRFCDV6061) Location Number of plants No. of Offices Total National 12* 9** 21 International - - - *Includes manufacturing sites and R&D facilities for standalone financial boundary # During the FY 25-26 the Generic business undertaking of the Company has been transferred to Alkem Wellness Limited (effective 01 October 2025). Accordingly, the BRSR indicators include the impact of Generic Business up to the date of transfer where applicable. For details, refer Note 3.36 of Standalone Financials Statements. **Includes 4 corporate offices and 5 directly owned depots Corporate Overview Statutory Reports Financial Statements Annual Report 2025-26 Alkem Laboratories Limited The Next Shape of Growth 19 Market served by the entity a. No. of Locations Sr. Locations Numbers 1. National (states) 28 states and 8 Union Territories 2. International (countries) More than 40 countries b. What is the contribution of exports as a percentage of the total turnover of the entity? 27.32% c. A brief on types of customers The Company caters to pharmaceutical firms, distributors, wholesalers, pharmacy chains, hospitals and other healthcare-related institutional customers across domestic and international markets. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled) Male Female Sr. Particulars Total (A) No. (B) % (B/A) No. (C) % (C/A) Employees 1 Permanent Employees (A) 17,453 16,931 97% 522 3% 2 Other than Permanent Employees (B) 291 270 93% 21 7% 3 Total Employees (A+B) 17,744 17,201 97% 543 3% Workers 4 Permanent Workers (C) 1,893 1,862 9 [Showing first 8,000 characters — download PDF for full document]